A NK-specific BCMA-targeted CAR constructed from 4 transgenes and intracellular signaling modalities derived from NKG2D, 2B4, and CD3ζ has shown translational results with potent antitumor activity against MM in various mice models (40). This evidence concerns the gene CD247 and Miyoshi myopathy.